Donanemab

• CAT Number: I042079
• CAS Number: 1931944-80-7
• Purity: ≥95%

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer’s disease research[1][2].
Donanemab is a humanized IgG1 antibody directed at an N-terminal pyroglutamate Aβ epitope that is present only in established plaques. Donanemab is specific for this epitope and shows no off-target binding to other Aβ species, neurotransmitters, or their receptors[2].

Reference

[1]. Stephen Loucian Lowe, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112.
 [Content Brief]

[2]. Mark A Mintun, et al. Donanemab in Early Alzheimer’s Disease. N Engl J Med. 2021 May 6;384(18):1691-1704.
 [Content Brief]